ASH 2025 – BeOne pulls away from Nurix
On efficacy, at least, BeOne’s BTK degrader shows an edge.
ASH 2025 – Gilead spills the beans on “fast” Car-T
It’s less about being fast, more about producing a better product.
ASH 2025 – BeOne assuages sonrotoclax safety concerns
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
ESMO Asia 2025 – Oric’s first-line gamble
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
BioNTech’s big gotistobart day approaches
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
ASH 2025 preview – toxicity worries hit BeOne’s sonrotoclax
The project has priority review, but deaths could raise eyebrows.
ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
ASH 2025 preview – another degrader fight
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
ASH 2025 preview – a new menin battleground
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
